Pace Of Bristol-Myers Squibb Company' Combo Cancer Trial Spooks Investors
Published: Jan 28, 2014
(Reuters) - Bristol-Myers Squibb Co (BMY.N) on Friday reported stronger-than-expected quarterly results, but its shares fell because of investors' jitters about the pace at which the company is developing a promising new combination of cancer drugs.
The stock dropped as much as 6.7 percent after company officials said on a conference call with investors that they were not yet planning a late-stage trial that would combine two of its high-profile drugs as a treatment for lung cancer.
Help employers find you! Check out all the jobs and post your resume.